A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

(2019) Kathleen N Moore et al.   LANCET ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

(2016) S. M. Keefe et al.   ANNALS OF ONCOLOGY

Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non–small Cell Lung Cancer

(2016) Hiroshi Nokihara et al.   CLINICAL THERAPEUTICS

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing

(2016) Andrew J. Clark et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis

(2016) Chien-Ju Lin et al.   Oncotarget

Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents

(2015) Andrew T Lucas et al.   Expert Opinion on Drug Metabolism & Toxicology

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

(2015) Carol Aghajanian et al.   GYNECOLOGIC ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

(2013) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents

(2013) Ryan F. Schell et al.   Nanomedicine-Nanotechnology Biology and Medicine

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

(2012) U Wagner et al.   BRITISH JOURNAL OF CANCER

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

(2011) R. Wendel Naumann et al.   DRUGS

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study

(2010) Giorgio Bolis et al.   EUROPEAN JOURNAL OF CANCER

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

(2010) Jalid Sehouli et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly paclitaxel in the treatment of recurrent ovarian cancer

(2010) Richard D. Baird et al.   Nature Reviews Clinical Oncology

Antivascular Actions of Microtubule-Binding Drugs

(2009) E. L. Schwartz   CLINICAL CANCER RESEARCH